<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05038358</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A00793-38</org_study_id>
    <nct_id>NCT05038358</nct_id>
  </id_info>
  <brief_title>Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms</brief_title>
  <acronym>CRC-ORGA 2</acronym>
  <official_title>Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms: a Patient-derived Tumoroids Prospective Collection From Systemic Treatment Naive Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal cancer is the third most common cancer worldwide and its progression-free survival&#xD;
      is still low, around 10 months. Thirthy to 50% of patients do not respond to chemotherapy&#xD;
      upon initiation of treatment, suggesting that early development of chemoresistance mechanisms&#xD;
      remains a major challenge. In order to better characterize these mechanisms, we aim to&#xD;
      develop a model of tumoroids derived from patients with a colorectal tumors prior to any&#xD;
      systemic anti cancer treatment. This project will both allow us to study the role of the&#xD;
      immunological microenvironment in chemoresistance and identify new predictive markers of&#xD;
      tumor response. It will then serve to develop innovative personalized medicine strategies by&#xD;
      targeting the newly identified mechanisms. This study should in fine help to improve the&#xD;
      cancer patient's care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of viable organoids for 60 days of culture maintenance.</measure>
    <time_frame>60 days of culture maintenance.</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Development of an Organoid Collection From Fresh Human Primary Colonic Tumor Tissue</condition>
  <eligibility>
    <study_pop>
      <textblock>
        colorectal adenocarcinoma, naive from neo-adjuvant chemotherapy, indication of surgical&#xD;
        resection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female over 18 years old.&#xD;
&#xD;
          -  Managed at the CHUGA for a colorectal adenocarcinoma&#xD;
&#xD;
          -  With an indication for immediate surgical resection as part of the care.&#xD;
&#xD;
          -  Patient naive from neo-adjuvant chemotherapy&#xD;
&#xD;
          -  Patient did not object to the CRC-ORGA-2 study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients protected by law (pregnant or breastfeeding women, minors, patients under&#xD;
             guardianship or trusteeship, persons deprived of their liberty or hospitalized under&#xD;
             duress).&#xD;
&#xD;
          -  Patients with positive HIV, HBV, HCV serology.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GAEL ROTH, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>university hospital of Grenoble alpes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GAEL ROTH, MD, PHD</last_name>
    <phone>04 76 76 51 68</phone>
    <phone_ext>0033</phone_ext>
    <email>GRoth@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ARNAUD MILLET, MD, PHD</last_name>
    <email>arnaud.millet@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>GAEL ROTH, MD, PHD</last_name>
      <email>GRoth@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>ARNAUD MILLET, MD,PHD</last_name>
      <email>arnaud.millet@inserm.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

